Cited by 151Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsNeurological Disease Mechanisms and Treatments

Protection of TGF-β1 against Neuroinflammation and Neurodegeneration in Aβ1–42-Induced Alzheimer’s Disease Model Rats

Open access
Chen, Jia-Hui, Ke, Kai-Fu, Lu, Jian-Hua, Qiu, Yi-Hua, Peng, Yu-Ping·2015·PLOS ONE

Abstract

Neuroinflammation has been reported to be associated with Alzheimer's disease (AD) pathogenesis. Neuroinflammation is generally considered as an outcome of glial activation; however, we recently demonstrated that T helper (Th)17 cells, a subpopulation of proinflammatory CD4+ T cells, are also involved in AD pathogenesis. Transforming growth factor (TGF)-β1, a cytokine that can be expressed in the brain, can be immunosuppressive, but its effects on lymphocyte-mediated neuroinflammation in AD pathogenesis have not been well addressed. In the current study we administered TGF-β1 via intracerebroventricle (ICV) and intranasal (IN) routes in AD model rats to investigate its antiinflammatory and neuroprotective effects. The AD rat model was prepared by bilateral hippocampal injection of amyloid-β (Aβ)1-42. TGF-β1 was administered via ICV one hour prior to Aβ1-42 injection or via both nares seven days after Aβ1-42 injection. ICV administration of TGF-β1 before Aβ1-42 injection remarkably ameliorated Aβ1-42-induced neurodegeneration and prevented Aβ1-42-induced increases in glia-derived proinflammatory mediators (TNF-α, IL-1β and iNOS), as well as T cell-derived proinflammatory cytokines (IFN-γ, IL-2, IL-17 and IL-22), in the hypothalamus, serum or cerebrospinal fluid (CSF) in a concentration-dependent manner. TGF-β1 pretreatment also prevented Aβ1-42-induced decreases in the neurotrophic factors, IGF-1, GDNF and BDNF, and in the antiinflammatory cytokine, IL-10. Similarly, IN administration of TGF-β1 after Aβ1-42 injection reduced neurodegeneration, elevation of proinflammatory mediators and cytokines, and reduction of neurotrophic and antiinflammatory factors, in the hypothalamus, serum or CSF. These findings suggest that TGF-β1 suppresses glial and T cell-mediated neuroinflammation and thereby alleviates AD-related neurodegeneration. The effectiveness of IN administered TGF-β1 in reducing Aβ1-42 neurotoxicity suggests a possible therapeutic approach in patients with AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0116549

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • After Aβ1-42 injection, pro-inflammatory cytokines increase and anti-inflammatory cytokines and BDNF protein levels and gene expression decrease.

    “Another study confirmed the increase in pro-inflammatory cytokines and reduced antiinflammatory cytokines and BDNF protein levels and gene expression after Aβ1–42 injection [155].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chen, J.-H., Ke, K.-F., Lu, J.-H., Qiu, Y.-H., & Peng, Y.-P.
Affiliations
Nantong University (CN)
Corresponding author
Peng, Yu-Ping
Venue
PLOS ONE
Published
2015-02-06
Volume
10
Issue
2
Pages
e0116549
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2047256501
Cited by
151
References
55
Citations by year
2026: 9 · 2025: 17 · 2024: 11 · 2023: 9 · 2022: 10 · 2021: 17 · 2020: 20 · 2019: 12 · 2018: 18 · 2017: 10 · 2016: 14 · 2015: 4
FWCI
11.29
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • University of Rochester
  • National Natural Science Foundation of China (31371182, 81271323)
  • Government of Jiangsu Province
  • Natural Science Foundation of Jiangsu Province
  • Priority Academic Program Development of Jiangsu Higher Education Institutions
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
TGF-β1, Alzheimer's disease, neuroinflammation, neurodegeneration, amyloid-beta 42, Th17 cells, intranasal administration, intracerebroventricular administration, neuroprotection, neurotrophic factors, brain-derived neurotrophic factor, IL-10, inflammatory cytokines, glial activation, hypothalamus
MeSH terms
Administration, Intranasal, Alzheimer Disease, Animals, Anti-Inflammatory Agents, Disease Models, Animal, Hypothalamus, Inflammation, Injections, Nerve Degeneration, Neuroglia, Peptide Fragments, Cytokines, Amyloid beta-Peptides, Rats, Sprague-Dawley, Neuroprotective Agents, Rats, Transforming Growth Factor beta1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review